Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,721 to 3,740 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | 689 of 947 547 of 945 | 14.9 points 10.6 to 19.1 | 1,892 | NCT06060457 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age |
| Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Required Additional Childcare | 390 of 1,190 220 of 701 | 1.4 points -3.0 to 5.7 | 1,891 | NCT02297815 Comparative Effectiveness of Antibiotics for Respiratory Infections |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Completion of TB Evaluation | 266 of 560 1,144 of 1,329 | -38.6 points -43.0 to -34.0 | 1,889 | NCT05640648 Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda |
| Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events | 568 of 945 594 of 943 | -2.9 points -7.3 to 1.5 | 1,888 | NCT00321620 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer |
| Dalteparin vs Placebo: serious adverse events | 133 of 934 66 of 950 | 7.3 points 4.5 to 10.1 | 1,884 | NCT00786474 Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study) |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR) | 3 of 942 12 of 940 | -1.0 points -1.9 to -0.1 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion | 1 of 942 11 of 940 | -1.1 points -2.0 to -0.4 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven) | 3 of 942 12 of 940 | -1.0 points -1.9 to -0.1 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death) | 4 of 942 12 of 940 | -0.9 points -1.8 to 0.0 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke | 40 of 942 77 of 940 | -3.9 points -6.2 to -1.8 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Graft Stenosis or Occlusion | 0 of 942 11 of 940 | -1.2 points -2.1 to -0.5 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke) | 4 of 942 13 of 940 | -1.0 points -2.0 to -0.1 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia | 40 of 942 82 of 940 | -4.5 points -6.7 to -2.3 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Protocol Defined MI | 34 of 942 58 of 940 | -2.6 points -4.6 to -0.6 | 1,882 | NCT01205776 EXCEL Clinical Trial |
| Amulet vs WATCHMAN (Control): deaths from any cause | 251 of 934 263 of 944 | -1.0 points -5.0 to 3.0 | 1,878 | NCT02879448 AMPLATZER™ Amulet™ LAA Occluder Trial |
| Amulet vs WATCHMAN (Control): serious adverse events | 542 of 934 535 of 944 | 1.4 points -3.1 to 5.8 | 1,878 | NCT02879448 AMPLATZER™ Amulet™ LAA Occluder Trial |
| Immediate Return of Results vs Delayed Return of Results: deaths from any cause | 3 of 953 4 of 921 | -0.1 points -0.8 to 0.5 | 1,874 | NCT06748040 Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy |
| EZ/Simva 10/40 mg vs Placebo: Hospitalization for Unstable Angina | 5 of 944 8 of 929 | -0.3 points -1.2 to 0.5 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) | 333 of 944 355 of 929 | -2.9 points -7.3 to 1.4 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Death (Any Cause) | 105 of 944 100 of 929 | 0.4 points -2.5 to 3.2 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=187"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=187
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT06060457-0dcbee98",
"title": "Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection",
"summary": "689 of 947 against 547 of 945; risk difference 14.9 points, 95% interval 10.6 to 19.1; NCT06060457, A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age",
"record": "/library/comparisons/NCT06060457-0dcbee98",
"nct_id": "NCT06060457",
"kind": "outcome",
"participants": 1892,
"risk_difference": {
"value": 0.14872473922104334,
"lower": 0.10604351635836287,
"upper": 0.1906493969788044
},
"group_1": "689 of 947",
"group_2": "547 of 945",
"difference": "14.9 points",
"interval": "10.6 to 19.1",
"trial_title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age"
},
{
"id": "NCT02297815-eb9a7ec7",
"title": "Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Required Additional Childcare",
"summary": "390 of 1190 against 220 of 701; risk difference 1.4 points, 95% interval -3.0 to 5.7; NCT02297815, Comparative Effectiveness of Antibiotics for Respiratory Infections",
"record": "/library/comparisons/NCT02297815-eb9a7ec7",
"nct_id": "NCT02297815",
"kind": "outcome",
"participants": 1891,
"risk_difference": {
"value": 0.013893717258658123,
"lower": -0.029984321026532465,
"upper": 0.05684991910481427
},
"group_1": "390 of 1,190",
"group_2": "220 of 701",
"difference": "1.4 points",
"interval": "-3.0 to 5.7",
"trial_title": "Comparative Effectiveness of Antibiotics for Respiratory Infections"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=188",
"request_id": "f0_ZoM5xQajp2GCb"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant